RE: A reminder from Inanaco 7839 . . .21 Apr 2024 22:48
The Genmab deal is worth nowhere near £600m to the valuation of the business.
That is absolute nonsense of the highest order.
To date £5.3m has been generated in terms of revenue.
The most it could possibly generate in terms of revenue is $624m under a lot of work and cost.
Incrementally you might argue there's somewhere between £50m and £200m if you're very lucky.
I can see a path to a £500m business but even that won't be easy.
Any ideas of £1+ are fantasy in my view and whilst there is the opportunity for great returns from these levels there is likely to be further dilution and challenges at all stages.